Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Researchers sought to determine whether early treatment strategies would be beneficial in patients with newly diagnosed, high-risk MDS.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Researchers compared outcomes for patients with multiple myeloma who received conditioning regimen of melphalan at a lower dose with outcomes using the standard dose.
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
A retrospective analysis of biopsies sought to correlate histologic findings with endoscopic findings in patients with upper GI tract GVHD after allogenic HSCT.
An evidence-based practice quality improvement project sought to determine the need, benefits, and challenges to implementing enteral nutrition in children undergoing hematopoietic stem cell transplantation.
Results of a phase 1/2 study determine the dosing, safety, and efficacy of axatilimab for refractory chronic graft-vs-host disease.
Randomized noninferiority study compared outcomes for patients with neutropenia after HSCT who followed a protective diet with those who followed a nonrestrictive diet.
Caregivers with approach-oriented coping strategy have less anxiety and depression symptoms, better quality of life.